Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma

Leukemia and Lymphoma

Volumn 57, Issue 6, 2016, Pages 1355-1362

  Liu, Wei Ping ^a   Wang, Xiao Pei ^a   Zheng, Wen ^a   Ping, Ling Yan ^a   Zhang, Chen ^a   Wang, Gui Qiang ^b   Song, Yu Qin ^a   Zhu, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

drug therapy, treatment outcome; hepatitis B; lymphoma; survival analysis

Indexed keywords

ADEFOVIR DIPIVOXIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; EPIRUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; RITUXIMAB; TELBIVUDINE; VINCRISTINE; VIRUS DNA; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; FEMALE; HEPATITIS B; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT VIRUS INFECTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; VIRUS REACTIVATION; ANTIBIOTIC PROPHYLAXIS; CANCER STAGING; COMPLICATION; DRUG EFFECTS; HEPATITIS B VIRUS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PHYSIOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BIOMARKERS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE; VIRUS ACTIVATION;

EID: 84953321100     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1116121     Document Type: Article

References (25)

1. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014; 11: 209-219.
2. Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol. 2012; 30: 3167-3173.
3. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-Analysis. Liver Int. 2008; 28: 28-38.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661-662.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-185.
6. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6: 531-561.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
8. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.
9. Welzel TM, Miley WJ, Parks TL, Goedert JJ, Whitby D, Ortiz-Conde BA. Real-Time PCR assay for detection and quantification of hepatitis B virus genotypes A to G. J Clin Microbiol. 2006; 44: 3325-3333.
10. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl). 2007; 120: 2159-2173.
11. Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014; 59: 2092-2100.
12. Lenci I, Tisone G, Di Paolo D, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-Transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol. 2011; 55: 587-593.
13. Chew E, Thursky K, Seymour JF. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: The need for continued vigilance. Leuk Lymphoma. 2014; 55: 938-939.
14. Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014; 7: 148-155.
15. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004; 83: 769-774.
16. Kim IK, Kim BG, Kim W, et al. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother. 2012; 56: 5511-5519.
17. Tamori A, Hino M, Kawamura E, et al. Prospective long-Term study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol. 2014; 29: 1715-1721.
18. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-Associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-Analysis and examination of FDA safety reports. Ann Oncol. 2011; 22: 1170-1180.
19. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-Analysis. J Clin Virol. 2013; 57: 209-214.
20. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007; 110: 2924-2930.
21. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003; 37: 1320-1328.
22. Xu L, Tu Z, Xu G, et al. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy. Mol Med Rep. 2014; 9: 1345-1350.
23. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597-1603.
24. Dai MS, Wu PF, Lu JJ, et al. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004;12:191-196.
25. Cho JH, Lim JH, Park GY, et al. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. Transpl Infect Dis. 2014; 16: 295-303.